Skip to Content

Tandem Diabetes Care Inc

TNDM: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$66.00KxxRgnbnsskb

Tandem Earnings: Softness in the Last Quarter Has Now Become More Pressing

Coming off the heels of a weak second quarter, Tandem's third quarter was more of the same. Though we made slight adjustments to our near-term expectations, this wasn’t enough to affect our $32 fair value estimate. While Tandem has recently made progress in containing operating expenses, the firm still has some years to go before returning to profitability. Similarly, projected returns on invested capital are likely to trail the weighted cost of capital through 2027, which keeps us from awarding Tandem any sort of economic moat at this point.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of TNDM so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center